Ocular Therapeutix (OCUL)
8.25
-0.55 (6.25%)
Upcoming Events
Latest Headlines
Form 4 OCULAR THERAPEUTIX, INC For: Jun 03 Filed by: Waheed Nadia
June 5, 2026 4:01 PM - SEC Filing
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026 7:00 AM - Globe NewsWire
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
June 4, 2026 7:00 AM - Globe NewsWire
Form 144 OCULAR THERAPEUTIX, INC Filed by: Waheed Nadia
June 3, 2026 4:07 PM - SEC Filing
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
June 2, 2026 7:00 AM - Globe NewsWire
Form 4 OCULAR THERAPEUTIX, INC For: May 26 Filed by: Dugel Pravin
May 28, 2026 4:52 PM - SEC Filing
Form 4 OCULAR THERAPEUTIX, INC For: May 26 Filed by: Kaiser Peter
May 28, 2026 4:51 PM - SEC Filing
Form 4 OCULAR THERAPEUTIX, INC For: May 26 Filed by: Heier Jeffrey S.
May 28, 2026 4:51 PM - SEC Filing
Form 4 OCULAR THERAPEUTIX, INC For: May 26 Filed by: Nayak Sanjay
May 28, 2026 4:50 PM - SEC Filing
Form 144 OCULAR THERAPEUTIX, INC Filed by: Nayak Sanjay
May 26, 2026 4:41 PM - SEC Filing
Form 144 OCULAR THERAPEUTIX, INC Filed by: Kaiser Peter
May 26, 2026 4:41 PM - SEC Filing
Form 144 OCULAR THERAPEUTIX, INC Filed by: Heier Jeffrey S.
May 26, 2026 4:40 PM - SEC Filing
Form 144 OCULAR THERAPEUTIX, INC Filed by: Dugel Pravin
May 26, 2026 4:38 PM - SEC Filing
Form SCHEDULE 13G/A OCULAR THERAPEUTIX, INC Filed by: Deep Track Capital, LP
May 15, 2026 8:46 AM - SEC Filing
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2026 7:00 AM - Globe NewsWire
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026 4:05 PM - Globe NewsWire
Form 10-Q OCULAR THERAPEUTIX, INC For: Mar 31
May 5, 2026 7:29 AM - SEC Filing
Ocular Therapeutix (OCUL) Misses Q1 EPS by 9c
May 5, 2026 7:22 AM - StreetInsider
Form 8-K OCULAR THERAPEUTIX, INC For: May 05
May 5, 2026 7:07 AM - SEC Filing
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
May 5, 2026 7:00 AM - Globe NewsWire
Form DEFA14A OCULAR THERAPEUTIX, INC
April 30, 2026 5:25 PM - SEC Filing
Form DEF 14A OCULAR THERAPEUTIX, INC For: Jun 11
April 30, 2026 5:18 PM - SEC Filing
Form ARS OCULAR THERAPEUTIX, INC For: Dec 31
April 30, 2026 4:40 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
April 30, 2026 6:54 AM - StreetInsider
Ocular Therapeutix enrolls first patient in SOL-X extension trial
April 29, 2026 7:00 AM - StreetInsider
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD
April 29, 2026 7:00 AM - Globe NewsWire
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026
April 28, 2026 7:00 AM - Globe NewsWire
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences
April 27, 2026 7:00 AM - Globe NewsWire
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
April 22, 2026 7:00 AM - Globe NewsWire
These are the best biotech stocks to own in 2026: BofA
April 19, 2026 10:00 AM - StreetInsider
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 14, 2026 7:00 AM - Globe NewsWire
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
April 14, 2026 6:48 AM - StreetInsider
Form 4 OCULAR THERAPEUTIX, INC For: Apr 09 Filed by: Dugel Pravin
April 13, 2026 5:15 PM - SEC Filing
William Blair stays Outperform on Ocular Therapeutix (OCUL) following Axpaxli data
April 13, 2026 3:07 PM - StreetInsider
Ocular Therapeutix reports additional week 52 data from wet AMD trial
April 13, 2026 7:01 AM - StreetInsider
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
April 13, 2026 7:00 AM - Globe NewsWire
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
April 1, 2026 7:01 AM - Globe NewsWire
Form SCHEDULE 13G/A OCULAR THERAPEUTIX, INC Filed by: VANGUARD GROUP INC
March 27, 2026 11:07 AM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
March 27, 2026 6:47 AM - StreetInsider
Ocular Therapeutix (OCUL) Reiterated at Market Outperform by Citizens Amid Litigation
March 24, 2026 4:23 AM - StreetInsider
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 9, 2026 4:01 PM - Globe NewsWire
Full Article List
